A Research Study of VCT220 in Adult Chinese Participants With Obesity

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

840

Participants

Timeline

Start Date

December 24, 2024

Primary Completion Date

October 25, 2025

Study Completion Date

March 27, 2026

Conditions

ObesityOverweight

Interventions

DRUG

VCT220

A small molecule GLP-1R drug, film coated tablet

DRUG

Placebo

Placebo tablets

Trial Locations (1)

Peking University People's Hospital （ There are multiple sites in this clinical trial）, Beijing

All Listed Sponsors

lead

Vincentage Pharma Co., Ltd

INDUSTRY

NCT06939296 - A Research Study of VCT220 in Adult Chinese Participants With Obesity | Biotech Hunter | Biotech Hunter